Login to Your Account



Phase III Cancer Vaccine Failure Deflates Oxford BioMedica

By Nuala Moran


Monday, July 14, 2008
LONDON - Oxford BioMedica plc's share price plunged 60.3 percent to 7.35 pence (US15 cents) on Friday when the company said the Phase III trial of its cancer vaccine TroVax would not reach its primary endpoint of overall survival in renal cancer. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription